Clinical Trial Update: E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update shows E7389 (eribulin mesylate) given as IV bolus on days 1 and 8 of a 21-day cycle in pre-treated patients with advanced or metastatic sof…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: Eisai Inc. | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-22